News
Talecris announces acquisition agreement with CSL
RESEARCH TRIANGLE PARK, NC —Talecris Biotherapeutics, Inc. today announced that it has signed a definitive merger agreement with CSL Limited under which CSL has agreed to acquire Talecris for $3.1 billion in cash. This amount includes net debt, which as of June 30, 2008 was approximately $1.2 billion, implying an equity value as of that date of about $1.9 billion.
